Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (November 2020)
26 slides from Cantargia Ab's investor presentation, Nov 24, 2020
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO NOVEMBER 2020
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: I. Introduction
I. INTRODUCTION
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Potentially more effective treatment against novel Pancreatic cancer Chemo combinations target in clinically validated Non-small cell lung cancer Chemo
Slide 5: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT Current owners (30 Sep 2020) • Positive interim data set - response rates higher than historical control PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS Swedbank Robur Funds 9.6% • Target IL1RAP found on most s
Slide 6: Cantargia addresses NSCLC & PDAC
Cantargia addresses NSCLC & PDAC 12% Lung Non-Small Cell Lung Cancer Pancreatic cancer Breast 12% Bowel Prostate 43% Stomach Incidence Liver 10% Larynx Cervix 2.1m Annual global incidences 0.5m Annual global incidences 7% Other 3% 3% 5% 6% 12% Fraction of cancer incidence 3% Fraction of cancer incid
Slide 7: II. Lead antibody CAN04
II. LEAD ANTIBODY CAN04
Slide 8: CAN04 – Superior IL-1 blocking approach
CAN04 – Superior IL-1 blocking approach Company Compound IL-1α IL-1β ADCC Indication/dev phase Cantargia CAN04 • Pancreatic cancer, NSCLC phase IIa ++ ++ ++ Xbiotech/ Xilonix • Autoimmunity, dermatology Janssen ++ – + • Pancreatic cancer, phase I Novartis Canakinumab • Autoimmunity, registered Gevok
Slide 9: CAN04 – Mechanism of action
CAN04 – Mechanism of action ADCC – Reduced activation Reduced Tumor cell death and infiltration of angiogenesis immunosuppressive cells Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated Fibroblast. NK = Natural Killer. MCP = Monocyte Chemoattractant Protein. MMP = Matrix
Slide 10: Counteracting tumor inflammation (IL-1 pathway) - validated in 10.000 patient study
Counteracting tumor inflammation (IL-1 pathway) - validated in 10.000 patient study Cantos trial (n=10,061) Canakinumab phase iii trials • Canakinumab (Novartis) ADJUVANT NSCLC • 1,500 patients • Reduced lung cancer incidence by 67% and death by 77% (CANOPY-A) • After surgery, no mets, placebo contr
Slide 11: Positive interim data – pancreatic cancer
Positive interim data– pancreatic cancer RECIST 1.1 Patient X CA19-9 Patient X 50 500 RECIST 1.1 (mm) 40 400 CA19-9 (kE/L) 30 300 20 200 10 100 0 0 0 10 20 30 0 10 20 30 Visit Visit RECIST 1.1 Patient Y CA19-9 Patient Y 40 150 RECIST 1.1 (mm) 30 CA19-9 (kE/L) 100 20 50 10 0 0 0 10 20 30 → CAN04 comb
Slide 12: Tumor shrinkage – NSCLC combination
Tumor shrinkage – NSCLC combination → CAN04 in combination with gem/cis in 1st line chemotherapy Patient → 6 of 9 evaluable patients with metastatic non-small cell lung 1 2 3 4 5 6 7 8 9 0 cancer (NSCLC) showed objective response including 1 Percent tumor reduction complete response (67% vs historic
Slide 13: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Interim Final Jun-19 Q3/Q4 H1 2021 2020 CANFOUR RESULTS PHASE I – Dose escalation with PHASE IIa – Dosage with assessment of therapeutic effect safety assessment Monotherapy Combination therapy, NSCLC (Dose group X) Recommended phase II dose Combination therapy, PDAC D
Slide 14: Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)
Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020) → Upregulation of both forms of IL-1 in PDX-model treated with Gem/Cis → CAN04 increases efficacy of chemotherapy regimes → CAN04 counteracts weight loss after chemotherapy SYNERGY WITH CHEMOTHERAPY IN LINE WITH CURRENT
Slide 15: Chemotherapy resistance
Chemotherapy resistance → Most chemotherapies induce chemoresistance already after a few months of therapy → Chemotherapy can upregulate both IL-1α and IL-1β → Blocking IL-1 signalling counteracts chemoresistance in preclinical models → High blood levels of inflammatory cytokines IL-1 and IL-6 leads
Slide 16: III. CAN04 oncology expansion and next steps
III. CAN04 ONCOLOGY EXPANSION AND NEXT STEPS
Slide 17: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need IL1RAP % of patients with IL1RAP CANTARGIA • Discovery of IL1RAP on cancer cells Cancer cell surface Stroma FOUNDATION • Antibodies against IL1RAP – antitumor effects 100 • IP on antibody therapy against IL1RAP 90 80 PRIMARY • Non-small cell lung cance
Slide 18: US Phase I clinical trial
US Phase I clinical trial → First patient started → Combination with checkpoint inhibitor in patients no longer responding to PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC, malignant melanoma and bladder cancer (18
Slide 19: CAN04 – NSCLC cancer strategy
CAN04 – NSCLC cancer strategy CAN04 + Docetaxel 2nd/3rd LINE CHEMOTHERAPY Pembrolizumab/platinum doublet progressors CAN04 + platinum doublet GEM/CIS COMBINATION 1st LINE CHEMOTHERAPY Pembrolizumab monotherapy (CANFOUR) progressors Targeted therapy progressors PT DOUBLET & PD1 / PDL1 1st LINE COMBIN
Slide 20: IV. Untapped possibilities in autoimmune diseases
IV. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES
Slide 21: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in mouse model → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on s
Slide 22: CAN10 – Systemic sclerosis and myocarditis
CAN10 – Systemic sclerosis and myocarditis CAN10 → Development process of CAN10 has included independent analysis of potential to treat c. 150 autoimmune and METHOD inflammatory diseases → Analysis included statements from key opinion leaders regarding e.g. scientific rationale of the blockade of th
Slide 23: CAN10 counteract inflammation in disease model
CAN10 counteract inflammation in disease model Total back score Isotype anti-IL-1β mCAN10 Dexamethasone → Mechanistic proof of concept for IL1RAP blockade in inflammatory driven psoriasis model 5 → Effect not dependent on IL-1β blockade 4 3 Score (0-8) 2 1 0 0 1 2 3 4 5 6 7 Days CAN10 HAS UNIQUE ANT
Slide 24: V. Milestones and summary
V. MILESTONES AND SUMMARY
Slide 25: Cantargia has several near-term value inflection points
Cantargia has several near-term value inflection points Newsflow next 6–9 months CAN04 → Phase IIa combination results PDAC and NSCLC → Next steps combination therapy PDAC and NSCLC → Phase IIa biomarker/biopsy results → New clinical trial in disease/combination outside CANFOUR CAN10 → Preclinical p
Slide 26: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • Positive interim data set and further phase II milestones during 2020 PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS • Cancer and large number of autoimmune/inflammatory diseases VISION OF BECOMING AN IMPORT